Foros de Conocimiento
medtronic PRODUCTOS
boston_scientific PRODUCTOS
TERUMO PRODUCTOS
Biotronik PRODUCTOS
Sirtex PRODUCTOS
Striker Neurovascular PRODUCTOS
BIOSENSORS PRODUCTOS

NOTICIAS


31 agosto 2016

Zenith endograft produces durable repair while long-term survival rates “remain poor”

Vascular News

Endovascular aneurysm repair (EVAR) using the Zenith endograft (Cook Medical) represents durable repair with a low risk of abdominal aortic aneurysm-related death at 14 years, according to data presented by Fabio Verzini, professor of Vascular Surgery, University of Perugia, Italy, at the Vascular Annual Meeting (9–11 June, National Harbor, USA). Despite this, the long-term survival rate of 24% shows that long-term outcomes for EVAR “remain poor,” Verzini said.

31 agosto 2016

Gore DrySeal Flex introducer sheath now commercially available

Vascular News

Gore has announced the commercial availability of the Gore DrySeal Flex introducer sheath, after recently gaining clearance for use by regulatory bodies in the USA, Europe, Canada, and Australia. The device is designed with a distinct combination of enhanced flexibility, kink resistance, and a hydrophilic coating to facilitate access to challenging anatomies and branch vessels, such as the common iliac arteries, during endovascular repair procedures.

26 agosto 2016

Getinge Group and GE launch new angiography integrated solution for Hybrid OR procedures in the US

Vascular News

Getinge Group announced on 25 August 2016 the launch of a new, highly flexible angiography solution for surgery, interventional and Hybrid operating room (OR) procedures in the United States. Jointly developed with GE Healthcare, a leader in providing transformational medical technologies, this integrated solution pairs the Magnus OR table system from Getinge Group’s Maquet brand with GE’s Discovery IGS 730 angiography system. According to Getinge Group, the combination of these two state-of-the art systems enables hospitals to expand the range of surgical procedures and interventions they offer patients as well as optimise the use of their Hybrid OR.

26 agosto 2016

Admedus set to launch vascular product

Vascular News

Admedus announced on 25 August 2016 that the manufacturing team have met the internal timeline of being prepared for the manufacture of VascuCel for the November launch date.

20 agosto 2016

Cardiovascular Systems releases 30-day results from LIBERTY 360° study

Vascular News

Cardiovascular Systems has released procedural and 30-day results from its LIBERTY 360° study in a late-breaking presentation at the 2016 Amputation Prevention Symposium (AMP; 10–13 August, Chicago, USA), showing high freedom from major adverse events across all Rutherford classes following endovascular interventions, including atherectomy.

23 agosto 2016

Lombard Medical closes US operations

Vascular News

Lombard Medical announced on 22 August 2016 “a significant operational restructuring and the exploration of strategic alternatives to enhance shareholder value” with the closure of its operations in the USA. The company added it would be allocating its resources to exclusively support the new Altura AAA stent graft system and the recently CE-marked IntelliFlex LP delivery system for Aorfix in the European Union, Japan and other key international markets.

12 agosto 2016

US branch/fenestrated EVAR use soars by over 500% in a decade

Vascular News

New US research indicates that there was a widespread and steady decline in elective open abdominal aortic aneurysm repairs for Medicare patients from 2003 to 2013, coinciding with a “dramatic” substitution of endovascular aneurysm repair (EVAR) across all geographic areas and a strikingly fast adoption of branched/fenestrated EVAR.

12 agosto 2016

WAVES trial shows 100% vein closure at one month with short return to work and normal activities

Vascular News

A post-market evaluation of the VenaSeal closure system (Medtronic) has found that, at one month, 100% of treated veins remained closed, quality of life scores improved significantly, and return to work and normal activity times were short. The data showed that treatment of multiple segments in one setting, large veins and superficial veins was safe, with further three-month follow-up now being analysed.

11 agosto 2016

First randomised Stellarex DCB data show 12-month outcomes superior to percutaneous transluminal angioplasty

Vascular News

Marianne Brodmann of Medical University Graz, Austria, has presented the final 12-month results of the Stellarex (Spectranetics) ILLUMENATE drug-coated balloon European randomised clinical trial (EU RCT) at the Amputation Prevention Symposium (AMP; 10–13 August, Chicago, USA). The EU RCT Trial enrolled 328 patients, 295 of whom were randomised to treatment with the Stellarex drug-coated balloon (DCB) or a percutaneous transluminal angioplasty (PTA).

Utilizamos cookies propias para el correcto funcionamiento del sitio web y mejorar nuestros servicios. Pulse el botón Aceptar todas para aceptar su uso. Puede cambiar la configuración u obtener más información en nuestra Política de cookies o pulsando Modificar configuración.